TASIGNA has a manageable safety profile after switching for imatinib resistance or intolerance, as seen in 2101, 2-year follow-up1

The 2101 study was a large, open-label, registration trial in imatinib-resistant or -intolerant patients with separate treatment arms for chronic phase (n=321) and accelerated phase (n=137) disease.

TASIGNA has a manageable safety and tolerability profile1

  • Pleural and pericardial effusions and complications of fluid retention occurred in < 1% of patients receiving TASIGNA1
  • Biochemical laboratory abnormalities were generally mild, transient, and manageable1,2
  • Between 24 and 48 months of follow-up, no new grade 3/4 nonhematologic AEs were reported and minimal new hematologic toxicity was observed3

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice a day.

  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; May 2017.
  2. Kantarjian HM, et al. Blood. 2011;117(4):1141-1145.
  3. Giles FJ, et al. Leukemia. 2013;27(1):107-112.